Obuchowski Nancy A, Buckler Andrew, Kinahan Paul, Chen-Mayer Heather, Petrick Nicholas, Barboriak Daniel P, Bullen Jennifer, Barnhart Huiman, Sullivan Daniel C
Quantitative Health Sciences, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195.
Elucid Bioimaging Inc., Wenham, Massachusetts.
Acad Radiol. 2016 Apr;23(4):496-506. doi: 10.1016/j.acra.2015.12.020. Epub 2016 Feb 18.
A major initiative of the Quantitative Imaging Biomarker Alliance is to develop standards-based documents called "Profiles," which describe one or more technical performance claims for a given imaging modality. The term "actor" denotes any entity (device, software, or person) whose performance must meet certain specifications for the claim to be met. The objective of this paper is to present the statistical issues in testing actors' conformance with the specifications. In particular, we present the general rationale and interpretation of the claims, the minimum requirements for testing whether an actor achieves the performance requirements, the study designs used for testing conformity, and the statistical analysis plan. We use three examples to illustrate the process: apparent diffusion coefficient in solid tumors measured by MRI, change in Perc 15 as a biomarker for the progression of emphysema, and percent change in solid tumor volume by computed tomography as a biomarker for lung cancer progression.
定量成像生物标志物联盟的一项主要举措是制定基于标准的文件,称为“概况”,其中描述了给定成像模态的一项或多项技术性能声明。术语“参与者”表示任何实体(设备、软件或人员),其性能必须满足某些规范才能满足声明要求。本文的目的是阐述测试参与者是否符合规范时的统计问题。具体而言,我们阐述声明的一般原理和解释、测试参与者是否达到性能要求的最低要求、用于测试合规性的研究设计以及统计分析计划。我们用三个例子来说明这个过程:通过MRI测量实体瘤中的表观扩散系数、作为肺气肿进展生物标志物的Perc 15变化,以及通过计算机断层扫描测量的实体瘤体积百分比变化作为肺癌进展的生物标志物。